Form 4: Arcus Biosciences CAO Sells Shares for Tax, 10b5-1 Plan

Arcus Biosciences' Chief Accounting Officer, Alexander Azoy, reported sales of 8,832 common shares over three days in December 2025, primarily to cover tax obligations and under a pre-arranged 10b5-1 trading plan.

Summary

• Alexander Azoy, Chief Accounting Officer of Arcus Biosciences, Inc. (RCUS), reported sales of common stock.
• Transactions occurred on December 16, 17, and 18, 2025.
• A total of 8,832 shares were sold across these three dates.
• The sales were primarily to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).
• The sales occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on May 22, 2025, and were not discretionary trades.
• Sales on December 18, 2025, were also effected pursuant to a Rule 10b5-1 trading plan adopted on June 6, 2025.
• Following these transactions, Azoy beneficially owns 18,531 shares of common stock, which includes unvested RSU grants.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While insider selling can sometimes be viewed negatively, these sales are largely non-discretionary, driven by tax obligations from RSU vesting, and partly executed under a pre-arranged 10b5-1 plan. This indicates a planned, administrative transaction rather than a reactive decision based on new information.

Positives

• The sales were largely non-discretionary, driven by tax withholding obligations upon RSU vesting, which is a common and expected practice for executives receiving equity compensation.
• The sales on December 18, 2025, were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned, rather than reactive, transaction, which helps mitigate concerns about insider trading.

Negatives

• Insider selling, even for tax purposes, can sometimes be perceived negatively by investors as it reduces the insider's direct equity stake in the company.

Future Outlook

NA

Management Comments

• Sales represent shares sold by the issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs.
• The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on May 22, 2025, and does not represent a discretionary trade by the reporting person.
• Sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 6, 2025.

Industry Context

This Form 4 filing is a routine disclosure of insider stock transactions and does not provide information relevant to broader industry trends or competitive landscape. Such filings are common across all industries for executives receiving equity compensation.

Corporate Governance

Stakeholder Impact

• Shareholders: The sale of shares by a Chief Accounting Officer, even for tax purposes, slightly reduces their direct ownership stake. However, the pre-planned nature (10b5-1) and tax-related reason mitigate significant concern, suggesting no material negative impact on shareholder confidence based solely on this filing.

Key Dates

Recommendation

This Form 4 reports routine insider sales by the Chief Accounting Officer, primarily for tax withholding on RSU vesting and partly under a pre-arranged 10b5-1 plan. Such transactions are common and generally not indicative of a change in the company's fundamental prospects or a discretionary decision to sell based on new information. Therefore, this filing alone does not warrant a change in investment recommendation; a 'hold' stance is appropriate, pending further company-specific or market-wide developments.

Keywords

Arcus Biosciences, RCUS, Insider Trading, Form 4, Alexander Azoy, Chief Accounting Officer, Stock Sale, 10b5-1 Plan, RSU Vesting, Equity Compensation